Biosynex, a French diagnostics company that specializes in point of care testing, completed the acquisition of ProciseDx, an in vitro diagnostics company with a proprietary instrument platform and portfolio of Point of Care diagnostic tests. "Biosynex has made Point of Care and Therapeutic Drug Monitoring a strategic focus. Biosynex have demonstrated our expertise in rapid testing through the Covid pandemic. We see many potential areas of expansion for the ProciseDx technology and we are excited to welcome ProciseDx to the Biosynex Group," Thierry Paper, Biosynex Deputy CEO.